New Insights into Pathogenesis and Treatment of ANCA-Associated Vasculitis: Autoantibodies and Beyond
暂无分享,去创建一个
[1] S. Gumina,et al. The Double Game Played by Th17 Cells in Infection: Host Defense and Immunopathology , 2022, Pathogens.
[2] H. Yazici,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria sets for three types of antineutrophilic cytoplasmic antibody-associated vasculitis , 2022, Current opinion in rheumatology.
[3] M. Yamaguchi,et al. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Complicated by Thrombotic Microangiopathy with Posterior Reversible Encephalopathy Syndrome Successfully Treated with Eculizumab: A Case Report. , 2022, Modern rheumatology case reports.
[4] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis , 2022, Annals of the Rheumatic Diseases.
[5] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis , 2022, Annals of the Rheumatic Diseases.
[6] P. Merkel,et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis , 2022, Annals of the Rheumatic Diseases.
[7] J. Burns,et al. Global epidemiology of vasculitis , 2021, Nature Reviews Rheumatology.
[8] B. Rovin,et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.
[9] I. Alobid,et al. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. , 2021, European journal of internal medicine.
[10] G. Guyatt,et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2021, Arthritis & rheumatology.
[11] T. Kaneko,et al. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab , 2021, International Archives of Allergy and Immunology.
[12] Y. Sheng,et al. Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Update: Genetic Pathogenesis , 2021, Frontiers in Immunology.
[13] P. Merkel,et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. , 2021, The New England journal of medicine.
[14] M. Strand,et al. Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis (EGPA). , 2021, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[15] P. Rutherford,et al. New insights into the epidemiology of ANCA-associated vasculitides in Germany: results from a claims data study. , 2021, Rheumatology.
[16] A. Gabrielli,et al. Rituximab for Eosinophilic Granulomatosis with Polyangiitis: a Systematic Review of Observational Studies. , 2021, Rheumatology.
[17] T. Takeuchi,et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systematic literature review. , 2020, Autoimmunity reviews.
[18] P. V. van Daele,et al. The value of anti-neutrophil cytoplasmic antibodies (ANCA) testing for the diagnosis of ANCA-associated vasculitis, a systematic review and meta-analysis. , 2020, Autoimmunity reviews.
[19] B. Rovin,et al. Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2020, ACR open rheumatology.
[20] M. Strand,et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. , 2020, The journal of allergy and clinical immunology. In practice.
[21] M. Caminati,et al. Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. , 2020, The journal of allergy and clinical immunology. In practice.
[22] S. Sartorelli,et al. Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study , 2020, Arthritis & rheumatology.
[23] E. Rhee,et al. Incidence, Clinical Features, and Outcomes of Late‐Onset Neutropenia From Rituximab for Autoimmune Disease , 2020, Arthritis & rheumatology.
[24] P. Heeringa,et al. Mycophenolic acid and 6-mercaptopurine both inhibit B-cell proliferation in granulomatosis with polyangiitis patients, whereas only mycophenolic acid inhibits B-cell IL-6 production , 2020, PloS one.
[25] A. Vaglio,et al. Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. , 2020, Rheumatology.
[26] L. Guillevin,et al. Rituximab treatment of ANCA-associated vasculitis , 2020, Expert opinion on biological therapy.
[27] S. Holdsworth,et al. Animal Models of ANCA Associated Vasculitis , 2020, Frontiers in Immunology.
[28] D. D'cruz,et al. Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines. , 2020, Rheumatology.
[29] A. Levin,et al. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. , 2020, The New England journal of medicine.
[30] F. Salvador. ANCA associated vasculitis. , 2020, European journal of internal medicine.
[31] J. Pirkle,et al. Narrative Review of Hypercoagulability in Small-Vessel Vasculitis , 2020, Kidney international reports.
[32] P. Merkel,et al. ANCA-associated vasculitis , 2020, Nature Reviews Disease Primers.
[33] D. Geetha,et al. ANCA-Associated Vasculitis: Core Curriculum 2020. , 2020, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[34] W. Koldingsnes,et al. Increasing incidence and prevalence of ANCA-associated vasculitis in Northern Norway. , 2019, Rheumatology.
[35] J. Belliere,et al. Glucocorticoid-free induction regimen in severe ANCA-associated vasculitis using a combination of rituximab and eculizumab. , 2019, Rheumatology.
[36] C. Vigneau,et al. The Presence of Renal IgG Deposits in Necrotizing Crescentic Glomerulonephritis Associated with ANCA Is Not Related to Worse Renal Clinical Outcomes , 2019, Kidney Diseases.
[37] J. Subra,et al. Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside. , 2019, Autoimmunity reviews.
[38] D. Jayne. Complement inhibition in ANCA vasculitis. , 2019, Nephrologie & therapeutique.
[39] Yichun Hu,et al. Measuring Circulating Complement Activation Products in Myeloperoxidase– and Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2019, Arthritis & rheumatology.
[40] L. Fugger,et al. A plasmid-encoded peptide from Staphylococcus aureus induces anti-myeloperoxidase nephritogenic autoimmunity , 2019, Nature Communications.
[41] S. Nishio,et al. The presence of anti-neutrophil extracellular trap antibody in patients with microscopic polyangiitis. , 2019, Rheumatology.
[42] E. Martins,et al. Increased renal damage in hypocomplementemic patients with ANCA-associated vasculitis: retrospective cohort study , 2019, Clinical Rheumatology.
[43] S. Ohlsson,et al. Neutrophils from ANCA-associated vasculitis patients show an increased capacity to activate the complement system via the alternative pathway after ANCA stimulation , 2019, PloS one.
[44] D. Jayne,et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis , 2019, RMD Open.
[45] Laura Martínez Valenzuela,et al. T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach , 2019, Clinical kidney journal.
[46] N. Zeleznik-Le,et al. NKG2D signaling certifies effector CD8 T cells for memory formation , 2019, Journal of Immunotherapy for Cancer.
[47] David W. Johnson,et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. , 2019, Kidney international.
[48] O. Witzke,et al. Th17 cells in renal inflammation and autoimmunity. , 2019, Autoimmunity reviews.
[49] A. Ishizu,et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis , 2018, Nature Reviews Rheumatology.
[50] Yong-Beom Park,et al. Low serum complement 3 level is associated with severe ANCA-associated vasculitis at diagnosis , 2018, Clinical and Experimental Nephrology.
[51] D. Jayne,et al. B cell therapy in ANCA-associated vasculitis: current and emerging treatment options , 2018, Nature Reviews Rheumatology.
[52] L. Guillevin,et al. Eosinophilic Granulomatosis with Polyangiitis (Churg–Strauss) , 2018, Seminars in Respiratory and Critical Care Medicine.
[53] E. Matteson,et al. Risk of Cardiovascular Disease and Venous Thromboembolism Among Patients With Incident ANCA‐Associated Vasculitis: A 20‐Year Population‐Based Cohort Study , 2018, Mayo Clinic proceedings.
[54] R. Manz,et al. Targeting B Cells and Plasma Cells in Autoimmune Diseases , 2018, Front. Immunol..
[55] Min Chen,et al. Complement Factor H Inhibits Anti-Neutrophil Cytoplasmic Autoantibody-Induced Neutrophil Activation by Interacting With Neutrophils , 2018, Front. Immunol..
[56] P. Fu,et al. Complement regulatory proteins in kidneys of patients with anti‐neutrophil cytoplasmic antibody (ANCA)‐associated vasculitis , 2018, Clinical and experimental immunology.
[57] V. Papayannopoulos. Neutrophil extracellular traps in immunity and disease , 2017, Nature Reviews Immunology.
[58] A. Vaglio,et al. Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis , 2017, Annals of the rheumatic diseases.
[59] E. Matteson,et al. The Epidemiology of Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis in Olmsted County, Minnesota , 2017, Arthritis & rheumatology.
[60] R. Voll,et al. Rituximab as Induction Therapy in Eosinophilic Granulomatosis with Polyangiitis Refractory to Conventional Immunosuppressive Treatment: A 36-Month Follow-Up Analysis. , 2017, The journal of allergy and clinical immunology. In practice.
[61] William H. Yang,et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: a phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial , 2017, The Lancet.
[62] S. Holdsworth,et al. ANCA-Associated Vasculitis: Pathogenesis, Models, and Preclinical Testing. , 2017, Seminars in nephrology.
[63] M. Jadoul,et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.
[64] M. Alba,et al. Interstital lung disease in ANCA vasculitis. , 2017, Autoimmunity reviews.
[65] D. Jayne,et al. Chronic nasal Staphylococcus aureus carriage identifies a subset of newly diagnosed granulomatosis with polyangiitis patients with high relapse rate , 2017, Rheumatology.
[66] S. Yancey,et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis , 2017, The New England journal of medicine.
[67] Hiroyuki Sato,et al. The influence of the Great East Japan earthquake on microscopic polyangiitis: A retrospective observational study , 2017, PloS one.
[68] J. Starmer,et al. Gene-Specific DNA Methylation Changes Predict Remission in Patients with ANCA-Associated Vasculitis. , 2017, Journal of the American Society of Nephrology : JASN.
[69] A. Vaglio,et al. Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectives , 2017, Internal and Emergency Medicine.
[70] R. Watts,et al. ANCA-associated vasculitis , 2017, Clinical medicine.
[71] Min Chen,et al. The functional activities of complement factor H are impaired in patients with ANCA-positive vasculitis. , 2017, Clinical immunology.
[72] C. Frampton,et al. Incidence of anti‐neutrophil cytoplasmic antibody‐associated vasculitis before and after the February 2011 Christchurch Earthquake , 2017, Internal medicine journal.
[73] Richard A Watts,et al. The incidence, prevalence and mortality of granulomatosis with polyangiitis in the UK Clinical Practice Research Datalink , 2016, Rheumatology.
[74] C. Demirkesen. Approach to cutaneous vasculitides with special emphasis on small vessel vasculitis: histopathology and direct immunofluorescence , 2017, Current opinion in rheumatology.
[75] A. Schwarting,et al. Genetics and pathophysiology of granulomatosis with polyangiitis (GPA) and its main autoantigen proteinase 3. , 2016, Molecular and cellular probes.
[76] T. Schall,et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study , 2016, PloS one.
[77] P. Merkel,et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis , 2016, Annals of the rheumatic diseases.
[78] W. Szczeklik,et al. Neurological manifestations in ANCA-associated vasculitis - assessment and treatment , 2016, Expert review of neurotherapeutics.
[79] G. Pamuk,et al. The epidemiology of antineutrophil cytoplasmic antibody-associated vasculitis in northwestern Turkey , 2016, Clinical Rheumatology.
[80] U. Specks,et al. Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes , 2015, Arthritis & rheumatology.
[81] P. Merkel,et al. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type , 2015, Annals of the rheumatic diseases.
[82] O. Dekkers,et al. Genetic variants in ANCA-associated vasculitis: a meta-analysis , 2015, Annals of the rheumatic diseases.
[83] P. Merkel,et al. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg–Strauss) , 2014, Annals of the rheumatic diseases.
[84] R. Marconi,et al. First report of FIP1L1-PDGFRα-positive eosinophilic granulomatosis with polyangiitis. , 2015, Rheumatology.
[85] C. Wang,et al. Neutrophil extracellular traps can activate alternative complement pathways , 2015, Clinical and experimental immunology.
[86] M. Klinger,et al. The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis , 2015, Clinical kidney journal.
[87] D. Roberts,et al. Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. , 2015, Journal of autoimmunity.
[88] P. Ravaud,et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. , 2014, The New England journal of medicine.
[89] C. Buzio,et al. Eosinophilic Granulomatosis with Polyangiitis: An Overview , 2014, Front. Immunol..
[90] P. Cacoub,et al. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. , 2014, Autoimmunity reviews.
[91] G. Berry,et al. T Cell–Macrophage Interactions and Granuloma Formation in Vasculitis , 2014, Front. Immunol..
[92] R. Falk,et al. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease , 2014, Nature Reviews Rheumatology.
[93] Min Chen,et al. The interaction between C5a and sphingosine-1-phosphate in neutrophils for antineutrophil cytoplasmic antibody mediated activation , 2014, Arthritis Research & Therapy.
[94] M. Mahler,et al. Novel Clinical and Diagnostic Aspects of Antineutrophil Cytoplasmic Antibodies , 2014, Journal of immunology research.
[95] Min Chen,et al. Coagulation and Fibrinolysis Index Profile in Patients with ANCA-Associated Vasculitis , 2014, PloS one.
[96] R. Falk,et al. B cell-mediated pathogenesis of ANCA-mediated vasculitis , 2014, Seminars in Immunopathology.
[97] D. D'cruz,et al. Diagnosis and classification of granulomatosis with polyangiitis (aka Wegener's granulomatosis). , 2014, Journal of autoimmunity.
[98] T. Schall,et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. , 2014, Journal of the American Society of Nephrology : JASN.
[99] K. Costenbader,et al. The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis. , 2013, Autoimmunity reviews.
[100] T. Tsuburai,et al. Decreases in the Numbers of Peripheral Blood Regulatory T Cells, and Increases in the Levels of Memory and Activated B Cells, in Patients with Active Eosinophilic Granulomatosis and Polyangiitis , 2013, Journal of Clinical Immunology.
[101] Stephan Ripke,et al. Association of granulomatosis with polyangiitis (Wegener's) with HLA-DPB1*04 and SEMA6A gene variants: evidence from genome-wide analysis. , 2013, Arthritis and rheumatism.
[102] A. Vaglio,et al. Eosinophilic granulomatosis with polyangiitis (Churg–Strauss): state of the art , 2013, Allergy.
[103] F. Moosig,et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients , 2012, Annals of the rheumatic diseases.
[104] C. Kallenberg,et al. Complement is crucial in the pathogenesis of ANCA-associated vasculitis. , 2013, Kidney international.
[105] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[106] T. Haferlach,et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. , 2012, The Journal of allergy and clinical immunology.
[107] Yichun Hu,et al. High Basal Activity of the PTPN22 Gain-of-Function Variant Blunts Leukocyte Responsiveness Negatively Affecting IL-10 Production in ANCA Vasculitis , 2012, PloS one.
[108] Panos Deloukas,et al. Genetically distinct subsets within ANCA-associated vasculitis. , 2012, The New England journal of medicine.
[109] N. Ortego-Centeno,et al. Manifestaciones otorrinolaringológicas de las vasculitis sistémicas , 2012 .
[110] Min Chen,et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis , 2012, Nature Reviews Nephrology.
[111] Min Chen,et al. p38MAPK, ERK and PI3K Signaling Pathways Are Involved in C5a-Primed Neutrophils for ANCA-Mediated Activation , 2012, PloS one.
[112] R. Kolbeck,et al. Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.
[113] P. Merkel,et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. , 2012, Rheumatology.
[114] M. Radić,et al. Drug-induced vasculitis: a clinical and pathological review. , 2012, The Netherlands journal of medicine.
[115] D. Scott,et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. , 2011, Rheumatology.
[116] J. Köhl,et al. TLR activation enhances C5a-induced pro-inflammatory responses by negatively modulating the second C5a receptor, C5L2 , 2011, European journal of immunology.
[117] C. Kallenberg. Pathogenesis of ANCA-associated vasculitides , 2011, Annals of the rheumatic diseases.
[118] L. Mouthon,et al. The Five-Factor Score Revisited: Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort , 2011, Medicine.
[119] M. Sanak,et al. Both Th2 and Th17 responses are involved in the pathogenesis of Churg-Strauss syndrome. , 2011, Clinical and experimental rheumatology.
[120] I. Bièche,et al. Interleukin-25: a cytokine linking eosinophils and adaptive immunity in Churg-Strauss syndrome. , 2010, Blood.
[121] T. Magnuson,et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. , 2010, The Journal of clinical investigation.
[122] M. Said. Upper Respiratory Tract Symptoms, Renal Involvement and Vasculitis: A Case Report and Review of Wegener Granulomatosis , 2010, Journal of clinical medicine research.
[123] P. Merkel,et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. , 2010, The New England journal of medicine.
[124] P. van Paassen,et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. , 2010, The New England journal of medicine.
[125] C. Pagnoux. Churg-Strauss syndrome: evolving concepts. , 2010, Discovery medicine.
[126] P. van Paassen,et al. T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? , 2010, Arthritis research & therapy.
[127] Sharon A Chung,et al. Microscopic polyangiitis. , 2010, Rheumatic diseases clinics of North America.
[128] Justine R. Smith,et al. Ocular disease in patients with ANCA-positive vasculitis , 2009, Journal of ocular biology, diseases, and informatics.
[129] L. Jacobsson,et al. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. , 2009, Rheumatology.
[130] P. Monk,et al. Complement component 5a (C5a). , 2009, The international journal of biochemistry & cell biology.
[131] Ashkan Emadi,et al. Cyclophosphamide and cancer: golden anniversary , 2009, Nature Reviews Clinical Oncology.
[132] R. Sinico,et al. Churg-Strauss angiitis. , 2009, Best practice & research. Clinical rheumatology.
[133] S. Nourshargh,et al. Cardiovascular , Pulmonary and Renal Pathology Experimental Autoimmune Vasculitis An Animal Model of Anti-neutrophil Cytoplasmic Autoantibody-Associated Systemic Vasculitis , 2009 .
[134] F. Luft,et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.
[135] David Steven Scott,et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) , 2008, Annals of the rheumatic diseases.
[136] L. Mouthon,et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. , 2008, The New England journal of medicine.
[137] Min Chen,et al. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. , 2008, Rheumatology.
[138] J. Zwerina,et al. Eotaxin-3 is involved in Churg-Strauss syndrome--a serum marker closely correlating with disease activity. , 2008, Rheumatology.
[139] E. Popa,et al. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener's granulomatosis. , 2007, Rheumatology.
[140] D. Scott,et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies , 2006, Annals of the rheumatic diseases.
[141] P. Heeringa,et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. , 2007, The American journal of pathology.
[142] P. van Paassen,et al. Mechanisms of Vasculitis: How Pauci-Immune Is ANCA-Associated Renal Vasculitis? , 2006, Nephron Experimental Nephrology.
[143] M. Hickey,et al. Anti-neutrophil cytoplasmic antibodies and effector CD4+ cells play nonredundant roles in anti-myeloperoxidase crescentic glomerulonephritis. , 2006, Journal of the American Society of Nephrology : JASN.
[144] Laura Pavone,et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. , 2005, Arthritis and rheumatism.
[145] C. Kallenberg,et al. Activation, Apoptosis, and Clearance of Neutrophils in Wegener's Granulomatosis , 2005, Annals of the New York Academy of Sciences.
[146] E. Lewis,et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[147] P. Bansal,et al. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[148] D. Roos,et al. Pathogenesis of diseases associated with antineutrophil cytoplasm autoantibodies. , 2004, Human immunology.
[149] C. Kallenberg,et al. The Th1 and Th2 Paradigm in ANCA-Associated Vasculitis , 2003, Kidney and Blood Pressure Research.
[150] U. Specks,et al. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. , 2003, The American journal of medicine.
[151] J. Stone. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. , 2003, Arthritis and rheumatism.
[152] M. González-Gay,et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. , 2003, Arthritis and rheumatism.
[153] P. Heeringa,et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. , 2002, The Journal of clinical investigation.
[154] R. Falk,et al. ANCA are pathogenic--oh yes they are! , 2002, Journal of the American Society of Nephrology : JASN.
[155] C. Kallenberg,et al. Staphylococcus aureus and Wegener's granulomatosis , 2001, Arthritis research.
[156] D. Scott,et al. Epidemiology of vasculitis in Europe , 2001, Annals of the rheumatic diseases.
[157] M. Daha,et al. Proteinase 3 enhances endothelial monocyte chemoattractant protein-1 production and induces increased adhesion of neutrophils to endothelial cells by upregulating intercellular cell adhesion molecule-1. , 2001, Journal of the American Society of Nephrology : JASN.
[158] W. Gross,et al. Elevated interleukin-4 and interleukin-13 production by T cell lines from patients with Churg-Strauss syndrome. , 2001, Arthritis and rheumatism.
[159] C. Savage,et al. Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. , 2000, Arthritis and rheumatism.
[160] M. Heller,et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. , 2000, Arthritis and rheumatism.
[161] S. Sasayama,et al. Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[162] M. Ernst,et al. Granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) but not granulocyte colony‐stimulating factor (G‐CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro , 2000, Clinical and experimental immunology.
[163] D. Scott,et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. , 2000, Arthritis and rheumatism.
[164] R J Falk,et al. International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA) , 1999, American journal of clinical pathology.
[165] W. Koldingsnes,et al. Severe intestinal involvement in Wegener's granulomatosis: report of two cases and review of the literature. , 1998, British journal of rheumatology.
[166] C. Gordon,et al. Development and initial validation of the Vasculitis Damage Index for the standardized clinical assessment of damage in the systemic vasculitides. , 1997, Arthritis and rheumatism.
[167] C. Kallenberg,et al. Autoantibodies to myeloperoxidase aggravate mild anti-glomerular-basement-membrane-mediated glomerular injury in the rat. , 1996, The American journal of pathology.
[168] C. Kallenberg,et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis , 1996 .
[169] T. Shibata,et al. Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. , 1995, Kidney international.
[170] R. Wetsel. Expression of the complement C5a anaphylatoxin receptor (C5aR) on non-myeloid cells. , 1995, Immunology letters.
[171] A. Fauci,et al. Classics in medicine , 1994 .
[172] C. Kallenberg,et al. Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model , 1993, The Journal of experimental medicine.
[173] M. Keogan,et al. Activation of normal neutrophils by anti‐neutrophil cytoplasm antibodies , 1992, Clinical and experimental immunology.
[174] Guy Hoffman,et al. Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.
[175] D A Bloch,et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. , 2010, Arthritis and rheumatism.
[176] T. Carey,et al. Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. , 1990, Annals of internal medicine.
[177] R J Falk,et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[178] A. Wiik,et al. Indirect immunofluorescence examination for IgG-ANCA in sera submitted for the 1st international workshop on ANCA, 1988. , 1989, APMIS. Supplementum.
[179] A. Fauci,et al. Suppression of human B lymphocyte function by cyclophosphamide. , 1982, Journal of immunology.